The ongoing CheckMate 649 is a randomized phase III study of nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced GC not expressing HER2. Here, ERBB2 is linked to gastric cancer.